Daily Brief Australia: Vection Technologies Ltd, Paradigm Biopharmaceuticals and more

Vection Technologies’ H124 activity report shows sustained momentum, with the group delivering 37% y-o-y revenue growth to A$11.9m. Total contract value (TCV) of A$16.7m was up 67% y-o-y, providing strong revenue visibility for the rest of FY24. As with Q1, we believe growth has been driven by the expansion of existing low-margin, one-off transactions into large multi-year deals. Expanding deals, rather than relying on new wins, underpin the opportunity for operationally geared growth, with management expecting to see the benefits of recent cost reduction measures in H2.

Edison Investment Research is terminating coverage on Atlantis Japan Growth Fund (AJG), Paradigm Biopharma (PAR), The European Smaller Companies Trust (ESCT), The Brunner Investment Trust (BUT), Channel Islands Property Fund (CIPF), Sequana Medical (SEQUA), RTW Biotech Opportunities (RTW), Itaconix (ITX), Endeavour Mining (EDV), Riverstone Credit Opportunities Income (RCOI) and Molecure (MOC). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.